Avedro is a privately held medical device and pharmaceutical company which is developing corneal cross-linking, a non-invasive treatment for refractive disorders and certain pathologies.
Avedro sells its products outside the US in 62 countries and has submitted an NDA to the FDA under orphan designation for its cross-linking system for keratoconus.
Avedro is also developing a next generation cross-linking technology, Photorefractive Intrastromal Cross-Linking (PiXL™), which is customized for each patient’s topography. Avedro believes that PiXL is an application for post-cataract ametropia and refractive correction, and has an annual potential of 10 million procedures. Avedro is based in Waltham, Massachusetts.